2-(Ethoxymethyl)pyrrolidine hydrochloride | 1956309-41-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 2-(Ethoxymethyl)pyrrolidine hydrochloride
• 英文别名: 2-(ethoxymethyl)pyrrolidine;hydrochloride
• CAS: 1956309-41-3
• 化学式: C7H16ClNO
• 分子量: 165.66
• InChiKey: RRBYXPBJKOSIKF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  21.3
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• [EN] ARYLCYCLOHEXYL PYRAZOLES AS NRF2 REGULATORS<br/>[FR] PYRAZOLES D'ARYLCYCLOHÉXYLE UTILISÉS EN TANT QUE RÉGULATEURS DE NRF2
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2017060855A1

  公开（公告）日：2017-04-13

  The present invention relates to arylcyclohexyl pyrazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 regulators.

  这项发明涉及芳基环己基吡唑化合物，制备方法，含有它们的药物组合物以及它们作为NRF2调节剂的用途。
• Isoquinoline compound and pharmaceutical use thereof
  申请人：Mitsubishi Pharma Corporation

  公开号：US20040248931A1

  公开（公告）日：2004-12-09

  The present invention relates to an isoquinoline compound represented by the following formula (I), an optically active form thereof, a pharmaceutically acceptable salt thereof, a water adduct thereof, a hydrate thereof and a solvate thereof, as well as an agent for the prophylaxis and/or treatment of a disease caused by hyperreactivity of poly(ADP-ribose)polymerase, containing the compound, and a poly(ADP-ribose)polymerase inhibitor containing the compound. In addition, this compound is useful as an agent for the prophylaxis and/or treatment of cerebral infarction, particularly as an agent for the prophylaxis and/or treatment of acute cerebral infarction. Furthermore, this compound is useful as a prophylactic and/or therapeutic agent that improves neurological symptoms associated with cerebral infarction, particularly acute cerebral infarction. 1 wherein the symbols are the same as defined in the description.

  本发明涉及一种异喹啉化合物，其由以下通式(I)表示，包括其光学活性形式、药学上可接受的盐、水合物、水合物和溶剂合物，以及用于预防和/或治疗由聚(ADP-核糖)聚合酶过度反应性引起的疾病的药物组合物，包含该化合物，以及包含该化合物的聚(ADP-核糖)聚合酶抑制剂。此外，该化合物可作为预防和/或治疗脑梗塞，特别是急性脑梗塞的药物。此外，该化合物可作为改善与脑梗塞，特别是急性脑梗塞相关的神经症状的预防和/或治疗药物。其中，符号的定义与说明书中的定义相同。
• ISOQUINOLINE COMPOUND AND PHARMACEUTICAL USE THEREOF
  申请人：Fujio Masakazu

  公开号：US20070161620A1

  公开（公告）日：2007-07-12

  The present invention relates to an isoquinoline compound represented by the following formula (I), an optically active form thereof, a pharmaceutically acceptable salt thereof, a water adduct thereof, a hydrate thereof and a solvate thereof, as well as an agent for the prophylaxis and/or treatment of a disease caused by hyperreactivity of poly(ADP-ribose)polymerase, containing the compound, and a poly(ADP-ribose)polymerase inhibitor containing the compound. In addition, this compound is useful as an agent for the prophylaxis and/or treatment of cerebral infarction, particularly as an agent for the prophylaxis and/or treatment of acute cerebral infarction. Furthermore, this compound is useful as a prophylactic and/or therapeutic agent that improves neurological symptoms associated with cerebral infarction, particularly acute cerebral infarction. wherein the symbols are the same as defined in the description.

  本发明涉及以下式(I)所表示的异喹啉化合物，其手性活性形式，其药学上可接受的盐，其水加合物，其水合物和其溶剂化物，以及包含该化合物的用于预防和/或治疗由多聚(ADP-核糖)聚合酶过度反应所致疾病的药剂和包含该化合物的多聚(ADP-核糖)聚合酶抑制剂。此外，该化合物可用作预防和/或治疗脑梗死的药剂，特别是作为预防和/或治疗急性脑梗死的药剂。此外，该化合物可用作改善与脑梗死相关的神经症状的预防性和/或治疗性药剂，特别是急性脑梗死。其中符号与描述中定义的相同。
• Arylcyclohexyl pyrazoles as NRF2 regulators
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：US10351530B2

  公开（公告）日：2019-07-16

  The present invention relates to arylcyclohexyl pyrazole compounds of Formula (I) methods of making them, pharmaceutical compositions containing them and their use as NRF2 regulators.

  本发明涉及式 (I) 的芳基环己基吡唑化合物 的制造方法、含有它们的药物组合物以及它们作为 NRF2 调节剂的用途。
• Biaryl pyrazoles as NRF2 regulators
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：US10364256B2

  公开（公告）日：2019-07-30

  The present invention relates to biaryl pyrazole compounds of Formula (I) methods of making them, pharmaceutical compositions containing them and their use as NRF2 regulators.

  本发明涉及式（I）的双芳基吡唑化合物 的制造方法、含有它们的药物组合物以及它们作为 NRF2 调节剂的用途。